How the White House's Proposed Rule on Federal Grants Rewrites the Rules of US Scientific Independence and Peer Review

At the heart of the United States' $1.1 trillion federal grant system lies a fundamental tension: should the public's money be directed by the independent consensus of scientific experts, or by the elected officials accountable to the taxpayers? For decades, the government has relied on independent peer review to drive breakthroughs from the internet to mRNA vaccines. Now, a sweeping 412-page proposed rule from the White House Office of Management and Budget (OMB) threatens to resolve that tension by firmly shifting power to political appointees.[1][4]

Published in the Federal Register on May 29, 2026, the "Regulation for Federal Financial Assistance" seeks to overhaul the Uniform Guidance that governs all federal grantmaking. The stated goal is to improve transparency, accountability, and alignment with the administration's priorities, ensuring taxpayer dollars are not wasted on projects that do not advance the national interest. However, the actual mechanisms introduced by the rule represent a structural dismantling of how science is currently funded.[5]

The most significant change involves how grants are approved. Under the current system, panels of independent scientists evaluate proposals based on scientific rigor and merit. The proposed rule introduces a mandatory "pre-issuance review" by senior political appointees across agencies like the National Institutes of Health and the National Science Foundation. These appointees would be tasked with ensuring that discretionary research awards demonstrably advance the president's policy priorities.[2][3]

Crucially, the rule explicitly states that independent peer review "remains advisory" and should not be treated as binding by these senior officials. By formally subordinating scientific consensus to political alignment, the regulation allows appointees to override expert panels and block funding for research that conflicts with the administration's agenda, regardless of its methodological soundness.[4][5]

The rule also dramatically expands the government's authority to cancel active research projects. Currently, grants are typically only terminated for fraud, financial mismanagement, or a failure to meet project milestones. The new provision allows agencies to terminate awards at any time if they are deemed inconsistent with program goals, federal agency priorities, or the evolving national interest.[3][5]

Researchers warn this creates immense financial and professional uncertainty. Multi-year studies—such as clinical trials for Alzheimer's disease or longitudinal climate models—could be abruptly defunded mid-stream if electoral outcomes shift the definition of the national interest. This instability makes it exceedingly difficult for universities to commit to long-term infrastructure or retain specialized talent.[4]

Another highly contested provision targets how scientific findings are shared with the public. The rule proposes making article processing charges—the fees required to publish in open-access, peer-reviewed journals—unallowable as grant expenses unless explicitly pre-approved by the funding agency.[1][4]

This creates a stark paradox for researchers. A 2022 White House mandate requires all federally funded research to be freely available to the public without delay by the end of 2025. By prohibiting the use of grant funds to cover the costs of open-access publishing, the rule shifts the financial burden entirely onto individual researchers and universities, potentially locking taxpayer-funded discoveries behind commercial paywalls if institutions cannot absorb the costs.[1]

The proposal also introduces strict new limitations on international research partnerships, extending a "domestic-first" framework across all federal agencies. While proponents market this as a necessary step to protect national security and intellectual property, scientific societies caution that the actual text will isolate American researchers from global data sharing and collaborative breakthroughs in fields like epidemiology and physics.[2][3][4]

The scientific community's response has been swift and overwhelmingly critical. Organizations including the American Institute of Physics, the Consortium of Social Science Associations, and the American Academy of Neurology have filed formal comments opposing the changes, warning that the rule will hinder scientific discovery and undercut the independent review that has anchored American biomedical research for decades.[2][3][4]

During the public comment period, which closed on July 13, 2026, the Federal Register received nearly 100,000 submissions. Critics argue that substituting ideological judgments for independent scientific review risks distorting research priorities and triggering a brain drain of top talent to countries with fewer political restrictions on inquiry.[1][6]

Proponents of the rule, rooted in the administration's "Restoring Gold Standard Science" executive orders, argue that the current grant system lacks sufficient oversight. They point to issues with reproducibility in scientific studies and the funding of projects they view as ideological rather than rigorous, asserting that elected officials must have the final say over how public funds are deployed.[5]

The OMB intends to issue a final rule that will take effect by October 1, 2026, applying to all federal awards made during the 2027 fiscal year. However, the sweeping nature of the changes guarantees a protracted legal battle.[2][5]

Several scientific organizations and universities are already preparing lawsuits to block the implementation of the rule, arguing it violates the Administrative Procedure Act by arbitrarily overturning decades of established grantmaking procedures. Until the courts rule, the future of the US scientific enterprise remains in a state of unprecedented limbo.[1][4]